CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Stock Information for CNS Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
CNS Pharmaceuticals Announces Reverse Stock Split

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.